Mercer Global Advisors Inc. ADV Lowers Stock Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Mercer Global Advisors Inc. ADV trimmed its stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Rating) by 10.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 14,266 shares of the medical device company’s stock after selling 1,749 shares during the period. Mercer Global Advisors Inc. ADV’s holdings in Tandem Diabetes Care were worth $641,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. lifted its position in shares of Tandem Diabetes Care by 2.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 6,246 shares of the medical device company’s stock worth $726,000 after purchasing an additional 164 shares during the period. Canada Pension Plan Investment Board lifted its position in shares of Tandem Diabetes Care by 3.4% in the 1st quarter. Canada Pension Plan Investment Board now owns 5,616 shares of the medical device company’s stock worth $654,000 after purchasing an additional 184 shares during the period. Legal & General Group Plc lifted its position in shares of Tandem Diabetes Care by 0.3% in the 2nd quarter. Legal & General Group Plc now owns 97,817 shares of the medical device company’s stock worth $5,790,000 after purchasing an additional 318 shares during the period. Signaturefd LLC lifted its position in shares of Tandem Diabetes Care by 106.0% in the 3rd quarter. Signaturefd LLC now owns 620 shares of the medical device company’s stock worth $30,000 after purchasing an additional 319 shares during the period. Finally, Treasurer of the State of North Carolina lifted its position in shares of Tandem Diabetes Care by 1.3% in the 3rd quarter. Treasurer of the State of North Carolina now owns 27,343 shares of the medical device company’s stock worth $1,308,000 after purchasing an additional 350 shares during the period. 96.50% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Tandem Diabetes Care

In other news, COO David B. Berger sold 10,000 shares of the stock in a transaction on Friday, March 3rd. The shares were sold at an average price of $41.19, for a total value of $411,900.00. Following the sale, the chief operating officer now owns 3,365 shares in the company, valued at $138,604.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, COO David B. Berger sold 10,000 shares of the stock in a transaction on Friday, March 3rd. The shares were sold at an average price of $41.19, for a total transaction of $411,900.00. Following the sale, the chief operating officer now directly owns 3,365 shares of the company’s stock, valued at $138,604.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Leigh Vosseller purchased 3,015 shares of the stock in a transaction that occurred on Friday, May 12th. The shares were purchased at an average cost of $32.77 per share, for a total transaction of $98,801.55. Following the completion of the acquisition, the chief financial officer now directly owns 5,660 shares of the company’s stock, valued at approximately $185,478.20. The disclosure for this purchase can be found here. Company insiders own 2.50% of the company’s stock.

Analysts Set New Price Targets

TNDM has been the subject of several research reports. StockNews.com raised shares of Tandem Diabetes Care from a “sell” rating to a “hold” rating in a research report on Saturday, May 13th. Barclays lowered their price target on shares of Tandem Diabetes Care from $76.00 to $71.00 in a research report on Thursday, February 23rd. Wolfe Research began coverage on shares of Tandem Diabetes Care in a research note on Thursday, January 26th. They set a “peer perform” rating for the company. Craig Hallum reduced their price objective on shares of Tandem Diabetes Care from $80.00 to $74.00 in a research note on Thursday, February 23rd. Finally, Raymond James lowered shares of Tandem Diabetes Care from an “outperform” rating to a “market perform” rating in a research note on Monday, April 24th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $53.14.

Tandem Diabetes Care Trading Down 5.1 %

Shares of Tandem Diabetes Care stock opened at $28.12 on Friday. The company has a debt-to-equity ratio of 0.84, a quick ratio of 3.66 and a current ratio of 4.43. Tandem Diabetes Care, Inc. has a 12-month low of $28.03 and a 12-month high of $75.47. The firm’s 50 day simple moving average is $38.45 and its two-hundred day simple moving average is $40.28.

Tandem Diabetes Care (NASDAQ:TNDM – Get Rating) last released its quarterly earnings data on Wednesday, February 22nd. The medical device company reported ($0.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.01. The firm had revenue of $223.45 million for the quarter, compared to analyst estimates of $221.99 million. Tandem Diabetes Care had a negative net margin of 25.64% and a negative return on equity of 17.77%. The business’s quarterly revenue was up 6.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.16 earnings per share. As a group, analysts expect that Tandem Diabetes Care, Inc. will post -1.02 earnings per share for the current fiscal year.

Tandem Diabetes Care Profile

(Get Rating)

Tandem Diabetes Care, Inc engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006, and is headquartered in San Diego, CA.